REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 30th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations
Contract Type FiledNovember 30th, 2023 Company IndustryThis REGISTRATION RIGHTS AGREEMENT (this “Agreement”), is made and entered into as of the date first above written, by and among FIBROBIOLOGICS LLC, a Delaware limited liability company and having a principal place of business at 16815 Royal Crest Drive, Suite 100, Houston, TX 77058 (the “Company”), GEM GLOBAL YIELD LLC SCS, a “société en commandite simple” formed under the laws of Luxembourg having LEI No. 213800CXBEHFXVLBZO92 having an address at 12C, rue Guillaume J. Kroll, L-1882 Luxembourg (“Purchaser”); and GEM YIELD BAHAMAS LIMITED, a limited company formed under the laws of the Commonwealth of the Bahamas and having an address at 3 Bayside Executive Park, West Bay Street & Blake Road, P.O. Box N-4875, Nassau, The Bahamas (“GYBL,” and together with Purchaser, the “Parties”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement (as defined below).
SHARE PURCHASE AGREEMENTShare Purchase Agreement • November 30th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 30th, 2023 Company Industry JurisdictionThis SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of the date first above written by and among FIBROBIOLOGICS LLC, a Delaware limited liability company and having a principal place of business at 16815 Royal Crest Drive, Suite 100, Houston, TX 77058 (the “Company”); GEM GLOBAL YIELD LLC SCS, a “société en commandite simple” formed under the laws of Luxembourg having LEI No. 213800CXBEHFXVLBZO92 having an address at 12C, rue Guillaume J. Kroll, L-1882 Luxembourg (the “Purchaser”); and GEM YIELD BAHAMAS LIMITED, a limited company formed under the laws of the Commonwealth of the Bahamas and having an address at 3 Bayside Executive Park, West Bay Street & Blake Road, P.O. Box N-4875, Nassau, The Bahamas (“GYBL,” and together with the Company and Purchaser, the “Parties”).
INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENTIntellectual Property Cross-License Agreement • November 30th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations • Texas
Contract Type FiledNovember 30th, 2023 Company Industry JurisdictionThis INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this “Agreement”), dated as of May 17, 2021 (the “Effective Date”), is made between SPINALCYTE LLC, a Texas limited liability company (“SpinalCyte”) and FIBROBIOLOGICS LLC, a Texas limited liability company (“FibroBiologics”). FibroBiologics and SpinalCyte are each referred to individually as a “Party” and collectively as the “Parties.”.
SUBLEASE AGREEMENTSublease Agreement • November 30th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations
Contract Type FiledNovember 30th, 2023 Company IndustryTHIS SUBLEASE AGREEMENT (“Sublease”), is made by and between United Fire & Casualty Company, an Iowa corporation doing business as United Fire Group (“Sublandlord”) and FibroBiologics, Inc., a Delaware corporation (“Subtenant”), and shall be effective as of the date set forth below Landlord’s signature (“Effective Date”). Sublandlord and Subtenant collectively shall be referred to herein as “Parties”, and individually as a “Party.”
AGREEMENTAgreement • November 30th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations • Texas
Contract Type FiledNovember 30th, 2023 Company Industry JurisdictionTHIS AGREEMENT (this “Agreement”), dated as of May 17, 2021 (the “Effective Date”), is made and entered into by and between SPINALCYTE LLC, a Texas limited liability company (“SpinalCyte”), and FIBROBIOLOGICS LLC, a Texas limited liability company (“FibroBiologics”). FibroBiologics and SpinalCyte are each referred to herein individually as a “Party” and collectively as the “Parties.”
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • November 30th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations • Texas
Contract Type FiledNovember 30th, 2023 Company Industry JurisdictionThis PATE T ASSIGNMENT AGREEMENT (this “Assignment”), dated as of May 17,202l (the “Effective Date”), is made and entered into by and between SPINALCYTE LLC, a Texas limited liability company (“SpinalCyte”) and FIBROBIOLOGICS LLC, a Texas limited liability company ( “FibroBiologics”). FibroBiologics and SpinalCyte are each referred to individually as a “ “ and collectively as the “Parties.”
AMENDMENT 1Patent Assignment Agreement • November 30th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations
Contract Type FiledNovember 30th, 2023 Company IndustryThis AMENDMENT 1 (“Amendment 1”) to the Patent Assignment Agreement (the “Assignment”) dated May 17, 2021 entered into by and between SPINALCYTE LLC, a Texas limited liability company (“SpinalCyte”), and FIBROBIOLOGICS, INC., a Delaware corporation (“FibroBiologics”), is effective as of August 2, 2022 (“Effective Date”). FibroBiologics and SpinalCyte are each referred to individually as a “Party” and collectively as the “Parties.”
Agreement Regarding Right of First NegotiationAgreement Regarding Right • November 30th, 2023 • FibroBiologics Inc. • Pharmaceutical preparations • Texas
Contract Type FiledNovember 30th, 2023 Company Industry JurisdictionThis Agreement Regarding Right of First Negotiation dated January 20, 2023, is by and between SpinalCyte LLC (“SpinalCyte”), and FibroBiologics, Inc. (“FibroBiologics”).